Entrada Therapeutics, Inc. (TRDA)
11.31
-0.67
(-5.59%)
USD |
NASDAQ |
Mar 20, 16:00
11.32
+0.01
(+0.09%)
After-Hours: 20:00
Entrada Therapeutics Research and Development Expense (Quarterly) : 33.07M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tyra Biosciences, Inc. | 28.05M |
| EyePoint Plc | 59.21M |
| Vertex Pharmaceuticals, Inc. | 973.70M |
| Kodiak Sciences, Inc. | 50.48M |
| Arcutis Biotherapeutics, Inc. | 20.45M |